ChoA Pharmaceutical조아제약
034940 · KOSDAQ · ₩034940 · 조아제약
₩1,704▼ ₩4 (0.23%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩59B | ₩63B | ₩63B | ₩69B | ₩58B |
| Cost of sales | ₩37B | ₩41B | ₩39B | ₩43B | ₩37B |
| Gross profit | ₩22B | ₩21B | ₩24B | ₩26B | ₩20B |
| Operating income | −₩6.6B | −₩9.6B | −₩6.8B | −₩482M | −₩7B |
| Net income | −₩7.4B | −₩10B | −₩11B | ₩515M | −₩8B |
| Net income to shareholders | −₩6.8B | −₩9.6B | −₩11B | ₩561M | −₩8B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩65B | ₩71B | ₩74B | ₩86B | ₩81B |
| Current assets | ₩35B | ₩40B | ₩42B | ₩48B | ₩47B |
| Cash and equivalents | ₩2.3B | ₩2.1B | ₩2B | ₩4.5B | ₩5.7B |
| Total liabilities | ₩43B | ₩43B | ₩35B | ₩34B | ₩32B |
| Current liabilities | ₩36B | ₩37B | ₩29B | ₩27B | ₩24B |
| Borrowings | ₩25B | ₩23B | ₩16B | ₩16B | ₩14B |
| Total equity | ₩22B | ₩29B | ₩39B | ₩51B | ₩48B |
| Shareholders' equity | ₩25B | ₩31B | ₩41B | ₩53B | ₩50B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩4.2B | −₩4.5B | −₩1.5B | −₩1.4B | −₩1.5B |
| Capital spending | ₩1.1B | ₩551M | ₩831M | ₩2.8B | ₩3.5B |
| Free cash flow | −₩5.3B | −₩5B | −₩2.3B | −₩4.2B | −₩5B |
Consolidated where available. Amounts in won.
Also known as: ChoA Pharmaceutical / 조아제약 / 034940 / KRX:034940
Source: KRX statistical information